Literature DB >> 3818897

The effect of circulating growth hormone-binding protein on metabolic clearance, distribution, and degradation of human growth hormone.

G Baumann, K D Amburn, T A Buchanan.   

Abstract

We recently described a specific binding protein for human GH (hGH) in human plasma, with which a substantial portion of circulating hGH is complexed. The biological function of the complexed fraction is unknown. To test the hypothesis that complexed hGH may have different in vivo kinetics than free hGH, we compared the MCRs, distribution volumes (Vd), and degradation rates of complexed and free [125I] hGH in the rat. A partially purified GH-binding protein preparation, generated by affinity chromatography on a hGH column, was used for this purpose. A mixture of hGH with binding protein (equivalent to the amount contained in 0.9 mL human plasma) was injected iv as a single dose. Parallel experiments were conducted with hGH in the absence of binding protein. Disappearance of total, immunoprecipitable, and trichloroacetic acid-precipitable radioactivity from rat plasma was followed, and MCR, Vd, and degradation rates were derived by standard mathematical techniques. The MCR was 6-fold slower for complexed than for free hGH (2.3 vs. 14 mL/min X kg), Vd was 4-fold smaller for complexed hGH than for free hGH (71 vs. 256 mL/kg), and initial degradation rate was 4.5-fold lower for complexed than for free hGH (13.2% vs. 59.9%/15 min). The Vd of complexed hGH was close to the intravascular volume, while the Vd for free hGH corresponded to the extracellular volume. We conclude that one function of the hGH-binding protein is relative confinement of hGH to the vascular compartment, thereby protecting it from degradation and prolonging its biological half-life.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3818897     DOI: 10.1210/jcem-64-4-657

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  14 in total

Review 1.  The role of pharmacokinetics in the development of biotechnologically derived agents.

Authors:  R J Wills; B L Ferraiolo
Journal:  Clin Pharmacokinet       Date:  1992-12       Impact factor: 6.447

Review 2.  Thyroid hormones and growth hormone secretion.

Authors:  R Valcavi; M Zini; I Portioli
Journal:  J Endocrinol Invest       Date:  1992-04       Impact factor: 4.256

Review 3.  The relevance of pharmacokinetics in the development of biotechnology products.

Authors:  S Toon
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1996 Apr-Jun       Impact factor: 2.441

Review 4.  Circulating growth hormone binding proteins.

Authors:  G Baumann; M A Shaw; K Amburn
Journal:  J Endocrinol Invest       Date:  1994-01       Impact factor: 4.256

Review 5.  The role of prolactin in mammary carcinoma.

Authors:  Charles V Clevenger; Priscilla A Furth; Susan E Hankinson; Linda A Schuler
Journal:  Endocr Rev       Date:  2003-02       Impact factor: 19.871

6.  Expression and localization of growth hormone receptor in the oviduct of cyclic and pregnant pigs and mid-implantation conceptuses.

Authors:  Martin Steffl; Markus Schweiger; Judith Mayer; Werner M Amselgruber
Journal:  Histochem Cell Biol       Date:  2009-03-18       Impact factor: 4.304

7.  Pharmacokinetics of radioiodinated human and ovine growth hormones in transgenic mice expressing bovine growth hormone.

Authors:  D Turyn; A Bartke
Journal:  Transgenic Res       Date:  1993-07       Impact factor: 2.788

8.  Interspecies scaling of clearance and volume of distribution data for five therapeutic proteins.

Authors:  J Mordenti; S A Chen; J A Moore; B L Ferraiolo; J D Green
Journal:  Pharm Res       Date:  1991-11       Impact factor: 4.200

Review 9.  Growth hormone receptor modulators.

Authors:  Vita Birzniece; Akira Sata; Ken K Y Ho
Journal:  Rev Endocr Metab Disord       Date:  2009-06       Impact factor: 6.514

10.  Influence of the high-affinity growth hormone (GH)-binding protein on plasma profiles of free and bound GH and on the apparent half-life of GH. Modeling analysis and clinical applications.

Authors:  J D Veldhuis; M L Johnson; L M Faunt; M Mercado; G Baumann
Journal:  J Clin Invest       Date:  1993-02       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.